Due to a delay in production, the oncological medicinal product Holoxan 1 g powder for solution for injection for intravenous use has been unavailable since 28 January 2026.
The firm Baxter SA-NV, the marketing authorisation holder of the medicinal product Holoxan 1 g containing the active substance ifosfamide, has informed the FAMHP of a temporary unavailability from 28 January 2026 until 31 December 2026. During this period, deliveries will still take place, but they will be insufficient to cover the total demand for Belgium.
The unavailability of Holoxan affects all countries where this medicinal product is marketed.
The experts of the FAMHP’s task force Unavailability make the following recommendations to physicians specialists and hospital pharmacists.
Priority for certain indications
1. The following indications have the highest priority:
- Ewing sarcomas in paediatric and adult patients – curative intent;
- soft tissue sarcomas in paediatric and adult patients – curative intent;
- malignant germ cell tumours in paediatric patients – curative intent;
- malignant brain tumours in initial treatment in paediatric patients – curative intent;
- lymphoma treatment in paediatric patients – curative intent;
- acute leukaemia in recurrent treatment in paediatric patients – curative intent;
- nephroblastomas in recurrent treatment in paediatric patients – curative intent.
2. Other priority indications:
- non-Hodgkin lymphomas in recurrent treatment in adult patients – curative intent;
- testicular tumours in recurrent treatment – curative intent;
- osteosarcomas in recurrent treatment – curative intent.
3. Indications for which temporary alternatives are available:
- lung carcinoma;
- breast carcinoma;
- ovarian carcinoma.
Monitoring by the FAMHP
The FAMHP is closely monitoring the situation and planned deliveries, and remains in regular contact with the company and the European Medicines Agency (EMA).